Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study

D. M. Chascsa, O. Y. Mousa, Surakit Pungpapong, N. Zhang, A. Chervenak, S. Nidamanuri, E. Rodriguez, D. Franco, K. Ryland, A. P. Keaveny, J. L. Huskey, M. Smith, Kunam Sudhakar Reddy, C. B. Taner, Hugo E Vargas, B. A. Aqel

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Waitlist time for kidney transplantation is long but may be shortened with the utilization of hepatitis C positive allografts. We retrospectively reviewed the course of 36 hepatitis C positive patients awaiting kidney transplantation at 2 large centers within the same health system, with near-identical care delivery models with the exception of timing of hepatitis C treatment, to determine the impact of timing of hepatitis C treatment on access to transplant, waitlist time, and treatment efficacy and tolerability. The majority of patients had hepatitis C genotype 1a or 1b, and all received direct acting antiviral therapy with 100% treatment response. One patient underwent transplantation in the pretransplant treatment group. The 1-year transplantation rate was 12.5% vs 67.9% (P =.0013) in those treated posttransplantation. The median waitlist time in the posttransplant group was 122 (interquartile range [IQR] 21.5, 531.0) days, which was significantly shorter than the center’s regional and national wait time. Pathologic review revealed no difference in allograft quality. Overall treatment related adverse events were not different between the 2 groups. A strategy of posttransplant hepatitis C treatment increased access to transplant and reduced waitlist time. Delaying treatment until after transplant did not appear to adversely affect recipients’ kidney allograft or overall survival.

Original languageEnglish (US)
Pages (from-to)2559-2565
Number of pages7
JournalAmerican Journal of Transplantation
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Hepatitis C
Kidney Transplantation
Multicenter Studies
Transplants
Allografts
Therapeutics
Transplantation
Antiviral Agents
Genotype
Kidney
Survival
Health

Keywords

  • cirrhosis
  • clinical research/practice
  • complication
  • donors and donation
  • extended criteria
  • infectious
  • infectious disease
  • kidney disease
  • kidney transplantation/nephrology
  • liver disease

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant : A multicenter study. / Chascsa, D. M.; Mousa, O. Y.; Pungpapong, Surakit; Zhang, N.; Chervenak, A.; Nidamanuri, S.; Rodriguez, E.; Franco, D.; Ryland, K.; Keaveny, A. P.; Huskey, J. L.; Smith, M.; Reddy, Kunam Sudhakar; Taner, C. B.; Vargas, Hugo E; Aqel, B. A.

In: American Journal of Transplantation, Vol. 18, No. 10, 01.10.2018, p. 2559-2565.

Research output: Contribution to journalArticle

Chascsa, DM, Mousa, OY, Pungpapong, S, Zhang, N, Chervenak, A, Nidamanuri, S, Rodriguez, E, Franco, D, Ryland, K, Keaveny, AP, Huskey, JL, Smith, M, Reddy, KS, Taner, CB, Vargas, HE & Aqel, BA 2018, 'Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study', American Journal of Transplantation, vol. 18, no. 10, pp. 2559-2565. https://doi.org/10.1111/ajt.14931
Chascsa, D. M. ; Mousa, O. Y. ; Pungpapong, Surakit ; Zhang, N. ; Chervenak, A. ; Nidamanuri, S. ; Rodriguez, E. ; Franco, D. ; Ryland, K. ; Keaveny, A. P. ; Huskey, J. L. ; Smith, M. ; Reddy, Kunam Sudhakar ; Taner, C. B. ; Vargas, Hugo E ; Aqel, B. A. / Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant : A multicenter study. In: American Journal of Transplantation. 2018 ; Vol. 18, No. 10. pp. 2559-2565.
@article{8606696379d24da19e8982349f3d2fd6,
title = "Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study",
abstract = "Waitlist time for kidney transplantation is long but may be shortened with the utilization of hepatitis C positive allografts. We retrospectively reviewed the course of 36 hepatitis C positive patients awaiting kidney transplantation at 2 large centers within the same health system, with near-identical care delivery models with the exception of timing of hepatitis C treatment, to determine the impact of timing of hepatitis C treatment on access to transplant, waitlist time, and treatment efficacy and tolerability. The majority of patients had hepatitis C genotype 1a or 1b, and all received direct acting antiviral therapy with 100{\%} treatment response. One patient underwent transplantation in the pretransplant treatment group. The 1-year transplantation rate was 12.5{\%} vs 67.9{\%} (P =.0013) in those treated posttransplantation. The median waitlist time in the posttransplant group was 122 (interquartile range [IQR] 21.5, 531.0) days, which was significantly shorter than the center’s regional and national wait time. Pathologic review revealed no difference in allograft quality. Overall treatment related adverse events were not different between the 2 groups. A strategy of posttransplant hepatitis C treatment increased access to transplant and reduced waitlist time. Delaying treatment until after transplant did not appear to adversely affect recipients’ kidney allograft or overall survival.",
keywords = "cirrhosis, clinical research/practice, complication, donors and donation, extended criteria, infectious, infectious disease, kidney disease, kidney transplantation/nephrology, liver disease",
author = "Chascsa, {D. M.} and Mousa, {O. Y.} and Surakit Pungpapong and N. Zhang and A. Chervenak and S. Nidamanuri and E. Rodriguez and D. Franco and K. Ryland and Keaveny, {A. P.} and Huskey, {J. L.} and M. Smith and Reddy, {Kunam Sudhakar} and Taner, {C. B.} and Vargas, {Hugo E} and Aqel, {B. A.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1111/ajt.14931",
language = "English (US)",
volume = "18",
pages = "2559--2565",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant

T2 - A multicenter study

AU - Chascsa, D. M.

AU - Mousa, O. Y.

AU - Pungpapong, Surakit

AU - Zhang, N.

AU - Chervenak, A.

AU - Nidamanuri, S.

AU - Rodriguez, E.

AU - Franco, D.

AU - Ryland, K.

AU - Keaveny, A. P.

AU - Huskey, J. L.

AU - Smith, M.

AU - Reddy, Kunam Sudhakar

AU - Taner, C. B.

AU - Vargas, Hugo E

AU - Aqel, B. A.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Waitlist time for kidney transplantation is long but may be shortened with the utilization of hepatitis C positive allografts. We retrospectively reviewed the course of 36 hepatitis C positive patients awaiting kidney transplantation at 2 large centers within the same health system, with near-identical care delivery models with the exception of timing of hepatitis C treatment, to determine the impact of timing of hepatitis C treatment on access to transplant, waitlist time, and treatment efficacy and tolerability. The majority of patients had hepatitis C genotype 1a or 1b, and all received direct acting antiviral therapy with 100% treatment response. One patient underwent transplantation in the pretransplant treatment group. The 1-year transplantation rate was 12.5% vs 67.9% (P =.0013) in those treated posttransplantation. The median waitlist time in the posttransplant group was 122 (interquartile range [IQR] 21.5, 531.0) days, which was significantly shorter than the center’s regional and national wait time. Pathologic review revealed no difference in allograft quality. Overall treatment related adverse events were not different between the 2 groups. A strategy of posttransplant hepatitis C treatment increased access to transplant and reduced waitlist time. Delaying treatment until after transplant did not appear to adversely affect recipients’ kidney allograft or overall survival.

AB - Waitlist time for kidney transplantation is long but may be shortened with the utilization of hepatitis C positive allografts. We retrospectively reviewed the course of 36 hepatitis C positive patients awaiting kidney transplantation at 2 large centers within the same health system, with near-identical care delivery models with the exception of timing of hepatitis C treatment, to determine the impact of timing of hepatitis C treatment on access to transplant, waitlist time, and treatment efficacy and tolerability. The majority of patients had hepatitis C genotype 1a or 1b, and all received direct acting antiviral therapy with 100% treatment response. One patient underwent transplantation in the pretransplant treatment group. The 1-year transplantation rate was 12.5% vs 67.9% (P =.0013) in those treated posttransplantation. The median waitlist time in the posttransplant group was 122 (interquartile range [IQR] 21.5, 531.0) days, which was significantly shorter than the center’s regional and national wait time. Pathologic review revealed no difference in allograft quality. Overall treatment related adverse events were not different between the 2 groups. A strategy of posttransplant hepatitis C treatment increased access to transplant and reduced waitlist time. Delaying treatment until after transplant did not appear to adversely affect recipients’ kidney allograft or overall survival.

KW - cirrhosis

KW - clinical research/practice

KW - complication

KW - donors and donation

KW - extended criteria

KW - infectious

KW - infectious disease

KW - kidney disease

KW - kidney transplantation/nephrology

KW - liver disease

UR - http://www.scopus.com/inward/record.url?scp=85053061394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053061394&partnerID=8YFLogxK

U2 - 10.1111/ajt.14931

DO - 10.1111/ajt.14931

M3 - Article

C2 - 29758123

AN - SCOPUS:85053061394

VL - 18

SP - 2559

EP - 2565

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 10

ER -